1613191-99-3

Basic information

• Product Name: 2-amino-6-fluoro-N-[5-fluoro-4-(4-{[4-(oxetan-3-yl)piperazin-1-yl]carbonyl}piperidin-1-yl)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
• CAS NO: 1613191-99-3
• Molecular Weight: 541.561
• Mol File: 1613191-99-3.mol

Chemical Properties

• CAS DataBase Reference: 2-amino-6-fluoro-N-[5-fluoro-4-(4-{[4-(oxetan-3-yl)piperazin-1-yl]carbonyl}piperidin-1-yl)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-6-fluoro-N-[5-fluoro-4-(4-{[4-(oxetan-3-yl)piperazin-1-yl]carbonyl}piperidin-1-yl)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide(1613191-99-3)
• EPA Substance Registry System: 2-amino-6-fluoro-N-[5-fluoro-4-(4-{[4-(oxetan-3-yl)piperazin-1-yl]carbonyl}piperidin-1-yl)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide(1613191-99-3)

Safety Data

• Hazardous Substances Data: 1613191-99-3(Hazardous Substances Data)

Usage

Core Structure

Pyrazolo[1,5-a]pyrimidine-3-carboxamide

Functional Groups

Amino
Fluoro
Piperazin-1-yl
Pyridin-3-yl
Oxetan-3-yl

Potential Pharmaceutical Properties

Requires further investigation
Potential applications in drug development and medicinal chemistry

Biological Activities

Not specified, needs further exploration

Interest for Study

Potential pharmaceutical properties
Complex organic structure
Multiple functional groups

Upstream product

• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 1254115-23-5 1-(oxetan-3-yl)-piperazine 
• 882738-24-1 1-benzyl 4-tert-butyl piperidine-1,4-dicarboxylate 
• 138007-24-6 4-tert-butyl piperidine-4-carboxylate 
• 1613193-36-4 tert-butyl 1-(3-bromo-5-fluoro-4-pyridyl)piperidine-4-carboxylate 
• 1613192-96-3 3-bromo-4-chloro-5-fluoropyridine hydrochloride 
• 1211540-92-9 3-bromo-4-chloro-5-fluoropyridine 
• 407-20-5 3-bromo-5-fluoropyridine 
• 1613192-04-3 1-[3-[(2-amino-6-fluoro-pyrazolo[1,5-a]pyrimidine-3-carbonyl)amino]-5-fluoro-4-pyridyl]piperidine-4-carboxylic acid hydrochloride 
• 1613192-03-2 1-[3-[(2-amino-6-fluoro-pyrazolo[1,5-a]pyrimidine-3-carbonyl)amino]-5-fluoro-4-pyridyl]piperidine-4-carboxylic acid trifluorocetate 
• 1613192-00-9 tert-butyl 1-[3-[(2-amino-6-fluoro-pyrazolo[1,5-a]pyrimidine-3-carbonyl)amino]-5-fluoro-4-pyridyl]piperidine-4-carboxyiate 
• 1613192-01-0 tert-butyl 1-(3-amino-5-fluoro-4-pyridyl)piperidine-4-carboxylate 
• 1613191-78-8 (6-chlorobenzotriazol-1-yl) 2-amino-6-fluoro-pyrazolo[1,5-a]pyrimidine-3-carboxylate 
• 1613191-77-7 2-amino-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid 

Relevant articles and documents

COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.

COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula (I) or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula (I-A) or a pharmaceutically acceptable salt, wherein the variables are as defined herein.